



Interactive Quarterly Performance Review (iQPR)

Strategic performance review

UFCW UPE

Jan - Dec 2022 vs Jan - Dec 2021

Optum Rx[®]

A NOTE FROM SUMIT DUTTA, MD

Focus on affordability

We're pleased to present your fourth quarter interactive Quarterly Performance Review (iQPR) results.

Enhancing access and affordability continue to be our top priorities. So, we continue to invest in unique solutions to address those challenges.

Our biosimilars strategy is just one way we're helping to provide patients and providers with high-quality affordable care, flexibility and choice, with no disruption to treatment. We'll continue to keep AbbVie's Humira® on our formulary in 2023 and will add up to three biosimilars – in the same position as the brand – starting with the first available biosimilar in 2023.

The availability of Humira biosimilars is one of the biggest opportunities in years to lower costs and increase accessibility for consumers who need expensive specialty medications. "The coming wave of biosimilars is a pivotal opportunity to reduce cost and increase access to care for millions of people," says Heather Cianfrocco, CEO.

In an ongoing commitment to health equity, we offer the Optum Rx® Care Partner program. Often, a local community pharmacy is the most accessible point of care for members – particularly for certain populations such as the elderly or transient. This program is designed to improve engagement, address intervention opportunities and provide members with the support they need with their local community clinicians.

With community care management as a central focus, this program closes gaps in care, extends clinical expertise and focuses on quality measures. By offering real-time medication reviews, local wellness support, advanced analytics and case management capabilities we help to extend care beyond our call center, so network partners can deliver timely and relevant care to meet members where they are.

We're grateful for your partnership and look forward to helping you use your data and quarterly results to build an effective health care approach that works best for your organization.

Sincerely,




Sumit Dutta, MD
Chief Medical Officer, Optum Rx

Summary of your plan


UFCW UPE

Reporting date range: Jan - Dec 2022 vs Jan - Dec 2021



Plan Paid PMPM

- UFCW UPE's PMPM is trending at 18.0% versus previous period
- Rebates provided a 23.3% offset resulting in net plan paid of \$146.26 PMPM
- Diabetes, Inflammatory Conditions, and Endocrine And Metabolic disease states accounted for 44.3% of overall plan paid and increased \$17.40 PMPM in total plan paid. The benchmark increased \$8.39 PMPM in these categories



Your outcomes

- Strategic Solutions have resulted in a total of \$138.95 PMPM plan savings



Your opportunities

- UFCW UPE's top opportunity for savings is the UM Opportunity. This would result in total plan savings of \$24.68 PMPM, which represents 12.9% of total plan spend
- Projected \$26,371 total healthcare (medical + pharmacy) savings from programs

Plan Performance - Plan Paid

UFCW UPE

Reporting date range: Jan - Dec 2022 vs Jan - Dec 2021
Benchmark: LABOR AND TRUST

Plan Paid

Total Plan Paid PMPM: \$190.57

Trend

Plan paid PMPM has increased 18.0% over the previous period driven primarily by drug mix in traditional and drug mix for specialty.

Specialty represents 1.0% of claims.



+7% over benchmark




+2.2% over benchmark



+20.9% over benchmark

Plan Paid PMPM

Current period PMPM of \$190.57 equates to \$3.8M in pharmacy spend. 36.3% of the spend is attributed to specialty medications.



Channel Management

Retail 90 ▲

PERCENTAGE OF RXs

38.4%

+23.1% over benchmark

Home delivery ▲

PERCENTAGE OF RXs

0.3%

-6.9% under benchmark

Optum Specialty Pharmacy ▲

PERCENTAGE OF SPECIALTY RXs

96.6%

+13.9% over benchmark

Clients may save money and improve adherence by shifting prescriptions to home delivery and retail 90.

Key Statistics


UFCW UPE

Reporting date range: Jan - Dec 2022 vs Jan - Dec 2021

Total Traditional Delivery Channel Specialty

Plan paid PMPM: \$190.57

Client totals



The key metrics here help highlight the changes UFCW UPE has experienced period over period.

- Eligibility has decreased by -303.
- Number of utilizers has decreased by -280.

Total Rxs
CURRENT
21,098
PREVIOUS
25,416
PERCENT CHANGE
-17.0%

Total plan paid
CURRENT
\$3,763,181
PREVIOUS
\$3,776,028
PERCENT CHANGE
-0.3%

Utilizers
CURRENT
1,167
PREVIOUS
1,447
PERCENT CHANGE
-19.4%

Key statistics with benchmark comparison

Benchmark comparison 1
LABOR AND TRUST

Benchmark comparison 2
COMMERCIAL

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 18.0%, compared to the benchmark trend of 11.0%
- Member Paid Share changed by -6.6% period over period, compared to the benchmark of -6.5%

Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Average age	54.1	52.2	3.7%	36.8	0.6%	36.9	0.4%
Plan paid PMPM	\$190.57	\$161.49	18.0%	\$109.72	11.0%	\$122.74	11.2%
Plan paid per Rx	\$178.37	\$148.57	20.1%	\$146.50	13.0%	\$147.29	11.5%
Rxs PMPM	1.068	1.087	-1.7%	0.749	-1.7%	0.833	-0.3%
Average days supply	48.8	47.1	3.5%	38.8	1.8%	38.5	2.1%
Days supply PMPM	52.1	51.2	1.7%	29.1	0.0%	32.1	1.8%
Member paid share	6.4%	6.8%	-6.6%	10.0%	-6.5%	11.1%	-3.3%
Member paid per Rx	\$12.22	\$10.98	11.3%	\$16.38	4.8%	\$18.42	7.3%
Generic dispensing rate	83.8%	83.0%	0.9%	86.3%	2.4%	84.8%	1.9%
GDR-without Vaccines	86.5%	87.0%	-0.6%	88.9%	-0.4%	88.1%	-1.2%
Home delivery rate	0.3%	0.1%	136.5%	7.1%	2.6%	5.4%	0.9%
Retail 90 rate	38.4%	36.5%	5.2%	15.3%	5.2%	18.4%	5.3%
Percent of specialty plan paid	36.3%	31.4%	15.5%	47.0%	3.9%	50.6%	1.3%

Outcomes Dashboard

UFCW UPE


Total Savings: \$138.95 PMPM

Program name	Date range	Savings type	Utilizers	Total savings	PMPM savings	% savings out of total plan paid	Description
Concurrent Drug Utilization Review	Jul - Sep 2022	Pharmacy - Plan Paid	568	\$422,935	\$86.92	45.6%	Concurrent Drug Utilization Review (cDUR) is performed during the point of sale when members are filling their prescriptions. This includes the ongoing monitoring of drug therapy to drive positive patient outcomes. It presents dispensing pharmacists with the opportunity to alert prescribers or to resolve potential clinical concerns associated with the member's prescription.
Rebate Performance	Jan - Dec 2022	Pharmacy - Plan Paid	N/A	\$875,021	\$44.31	23.3%	Rebate offsets assist in reaching lowest net cost for prescription medications. Opportunities exist to improve rebates by adopting alternate OptumRx Formularies.
Utilization Management	Jan - Dec 2022	Pharmacy - Plan Paid	100	\$152,543	\$7.72	4.1%	The OptumRx UM programs ensure your members meet appropriate clinical criteria before initiation of certain drug therapy. This confirms your member's therapy is safe and consistent with accepted therapeutic guidelines; resulting in plan savings. UM may include Prior Authorization (PA), Quantity Limits (QL) and Step Therapy (ST).
PreCheck MyScript	Jan - Dec 2022	Pharmacy - Member Paid	376	\$97	\$0.00	0.0%	PreCheck MyScript simplifies the prescribing experience for members and physicians by providing real-time, member-specific medication pricing and coverage information as well as formulary-specific alternatives at the point of prescribing.
Copay Assistance	Jan - Dec 2022	Pharmacy - Member Paid	17	\$21,363	\$1.08	8.3%	Manufacturer copay assistance can be an asset to both members and clients because it helps offset the financial burden to your members which can have the additional benefit of better medication adherence and dedication to treatment.

Utilization management savings: \$7.72 PMPM

Your program savings: \$152.5K

Ensuring patients meet appropriate clinical criteria when initiating medication therapy not only helps to ensure that the patient is being treated safely according to guidelines, but also drives significant savings for both UFCW UPE and for members. UFCW UPE has realized over \$152.5K in savings. Based on a study by OptumRx, leveraging UM strategies that drive members to appropriate and often lower cost medications for treatment can save a member up to \$620 annually in out of pocket copayments.



Prior authorization

PMPM SAVINGS

\$7.55

NUMBER OF MEMBERS IMPACTED

60

NUMBER OF INTERVENTIONS

67

Quantity limits

PMPM SAVINGS

\$0.18

NUMBER OF MEMBERS IMPACTED

40

NUMBER OF INTERVENTIONS

45

QL savings is based only on Maximum Daily Dose edits.

Top 5 therapy classes by: Prior Authorization Quantity Limits Step Therapy



Prior authorization savings from top 5 therapeutic class interventions

GPI-4 Description	Number of cases	Plan paid savings
Chronic Inflammatory Disease	13	\$140,440
Anti-Obesity Agents	7	\$7,777
Impotence Agents	44	\$868
Acne Products	1	\$0
Anthelmintics	1	\$0

Top 5 therapy classes by: Prior Authorization Quantity Limits Step Therapy



Quantity limits savings from top 5 therapeutic class interventions

GPI-4 Description	Number of cases	Plan paid savings
Migraine Products	15	\$1,392
Proton Pump Inhibitors	25	\$1,259
Nonsteroidal Anti-Inflammatory Agents (NSAIDs)	3	\$733
Opioid Partial Agonists	1	\$72
Antiemetics	1	\$0


Rebate Performance

UFCW UPE

Outcomes date range: Jan - Dec 2022

Benchmark: LABOR AND TRUST

Current rebate value: \$44.31 PMPM



Rebate impact on Plan Paid PMPM

Managing drug spend to a lowest net cost PMPM is achieved through adoption of high performing formulary strategies and driving to lowest net cost products when clinically appropriate. UFCW UPE's members adherence to the formulary has earned an offset on PMPM costs, yielding a net plan paid PMPM of \$146.26, versus plan paid PMPM of \$190.57.

Net financial PMPM performance

	Drug cost	Member Paid	Plan Paid	Rebates	Net plan paid
Traditional	\$133.85	\$11.30	\$121.47	\$28.84	\$92.63
Specialty	\$70.86	\$1.76	\$69.10	\$15.47	\$53.63
Total	\$204.72	\$13.06	\$190.57	\$44.31	\$146.26

Total estimated rebate yield for reporting period: **\$875.0K**

Total savings: \$86.92 PMPM

Savings outcomes analysis summary



Concurrent Drug Utilization Review (cDUR) is performed during the point of sale when members are filling their prescriptions. This review involves the ongoing monitoring of drug therapy to ensure positive patient outcomes. It presents dispensing pharmacists with the opportunity to alert prescribers or to resolve potential clinical concerns associated with the member's prescription. Potential clinical opportunities include but are not limited to drug-drug interactions, duplicate therapy, over or under- utilization, and excessive or insufficient dosing. This type of review allows therapy for a patient to be altered, if necessary, to ensure safe and appropriate medication utilization. With OptumRx cDUR program, UFCW UPE has realized \$422,935 in total savings, with 57.3% of interventions that occurred out of 6,399 total claims.

Top 5 interventions

Sort Top 5 by: Number of interventions Total savings

Duration NUMBER OF INTERVENTIONS 1,534 TOTAL SAVINGS \$316,505 % OF INTERVENTIONS 24.0% Member is taking a medication for longer and/or at a higher dose than recommended.	Drug-Drug Interaction NUMBER OF INTERVENTIONS 1,329 TOTAL SAVINGS \$41,749 % OF INTERVENTIONS 20.8% Member is taking 2 interacting medications and/or medication classes.	Duplicate Rx NUMBER OF INTERVENTIONS 457 TOTAL SAVINGS \$40,863 % OF INTERVENTIONS 7.1% Member is taking 2 medications with the same ingredient.
Duplicate Therapy NUMBER OF INTERVENTIONS 245 TOTAL SAVINGS \$16,501 % OF INTERVENTIONS 3.8% Member is taking 2 medications in the same drug class.	Refill Too Soon NUMBER OF INTERVENTIONS 61 TOTAL SAVINGS \$4,755 % OF INTERVENTIONS 1.0% Member tried refilling with medication still left on hand from prior fill.	All other NUMBER OF INTERVENTIONS 38 TOTAL SAVINGS \$2,562 % OF INTERVENTIONS 0.6%

PreCheck MyScript Program Outcomes

UFCW UPE

Outcomes date range: Jan - Dec 2022

Total member savings: \$97

Average member savings per alternative switched: \$5.71

During this reporting period, PreCheck MyScript (PCMS) was used for 22.8% of your eligible members for a benefit check in their physician's office.


- PCMS was used by physicians to submit 1,202 trial claims for members
- 17 prescriptions were converted to Preferred Alternatives when PCMS was used
- 19.1% (594) of physicians currently utilize PCMS compared to 16.6% (600) of physicians in the prior period



DID YOU KNOW?

Recent studies demonstrated that PreCheck MyScript technology is enabling improvement in affordability and health outcomes, including increase in medication adherence of up to 4% for selected chronic conditions.

Physicians utilization



-25.9% under benchmark


TOTAL PHYSICIANS

3,109

PHYSICIANS UTILIZING PCMS

594

Alternative conversions



+17.6% over benchmark

ALTERNATIVES OFFERED

86

ALTERNATIVES CONVERTED

17

Top 5 Preferred Alternatives converted representing 94.1% of all Preferred Alternative conversion activities




Preferred alternative	RXs	Drug type
ALBUTEROL SULFATE HFA	11	Generic
METOPROLOL SUCCINATE ER	2	Generic
LEVEMIR FLEXTOUCH	1	Brand
SUCRALFATE	1	Generic
TORSEMIDE	1	Generic


Optum Specialty Pharmacy Copay Assistance Analysis

UFCW UPE
Reporting date range: Jan - Dec 2022

Total member copay assistance: \$21,363



Member out of pocket cost



Copay assistance may benefit your members and your company in offsetting the financial burden and potentially improving members' medication adherence and dedication to treatment. This period, UFCW UPE members leveraged assistance provided by manufacturer copay card:

- \$4,020 member out-of-pocket copay with manufacturer copay card
- \$21,363 of total member savings
- Inflammatory Conditions had the highest copay assistance

Top 5 disease states with copay assistance

Sort by: Copay assistance Rx count

Disease state	Utilizers	Rx count	Member copay before assistance	Copay assistance amount	Member copay after assistance	Plan paid
Inflammatory Conditions	12	77	\$18,025	\$15,262	\$2,763	\$579,165
Hepatitis	2	4	\$4,443	\$4,428	\$15	\$31,189
Endocrine And Metabolic	2	18	\$2,553	\$1,361	\$1,192	\$351,174
Osteoporosis	1	2	\$363	\$313	\$50	\$2,426

Sort by: Copay assistance Rx count

Disease state	Utilizers	Rx count	Member copay before assistance	Copay assistance amount	Member copay after assistance	Plan paid
Inflammatory Conditions	12	77	\$18,025	\$15,262	\$2,763	\$579,165
Endocrine And Metabolic	2	18	\$2,553	\$1,361	\$1,192	\$351,174
Hepatitis	2	4	\$4,443	\$4,428	\$15	\$31,189
Osteoporosis	1	2	\$363	\$313	\$50	\$2,426

Opportunity Dashboard

UFCW UPE

Opportunities date range: Jan - Dec 2022

Total Plan Paid PMPM Opportunities: \$38.67

Program name	Savings type	Utilizers	Total savings	PMPM savings	Pct savings	Description
Utilization Management (UM)	Pharmacy - Plan Paid	377	\$487,328	\$24.68	12.9%	The OptumRx UM programs ensure your members meet appropriate clinical criteria before initiation of certain drug therapy. This confirms your member's therapy is safe and consistent with accepted therapeutic guidelines; resulting in plan savings. UM may include Prior Authorization (PA), Quantity Limits (QL) and Step Therapy (ST).
Vigilant Drug Opportunity	Pharmacy - Plan Paid	70	\$156,732	\$7.94	4.2%	The OptumRx Vigilant Drug Program helps ensure clinically appropriate medications and minimize drug spend through targeted exclusion strategies that remove certain unnecessary medications from coverage.
Accumulator Adjustment Opportunity	Pharmacy - Plan Paid	177	\$119,483	\$6.05	3.2%	Accumulator adjustment maintains the integrity and intention of the pharmacy benefit by providing a real time solution to exclude manufacturer copay card dollars from members' accumulators. The opportunity represents the total potential copay card dollars that would be identified and prevented from applying to member accumulators.
Home Delivery Opportunity	Pharmacy - Plan Paid	560	N/A	N/A	N/A	OptumRx Home Delivery (HD) offers members and clients lower costs and improved healthcare outcomes while enhancing convenience and patient safety. HD drives significantly higher dispensing accuracy and adherence compared to retail.
Diabetes Management Opportunity	Book of Business - Plan Paid	206	\$22,907	\$1.16	0.6%	The OptumRx Diabetes Management program is a holistic solution designed to meet our clients' specific needs. By keeping members healthy we can help reduce complications and progression as well as curb medical visits and hospitalizations; leading to lower healthcare costs.
Opioid Opportunity	Book of Business - Healthcare	104	\$7,805	\$1.24	0.2%	The Opioid Risk Management program is a comprehensive solution that uses advanced analytics and evidence-based clinical rules to decrease over prescribing, prevent opioid misuse, as well as identify and intervene with high-risk members. Date range for this program is Sep - Dec 2022.
Meds on Track/Adherence Opportunity	Healthcare	101	\$26,371	\$1.34	0.3%	Medication non-adherence can lead to complications that require costly and potentially avoidable health care services. With the OptumRx Meds on Track program, we identify and engage members to improve medication adherence and deliver improved health outcomes.

Home Delivery Opportunity Analysis

UFCW UPE

Opportunities date range: Jan - Dec 2022

Total retail maintenance utilizers: 560

Reducing prescription drug cost



- Home Delivery (HD) offers deeper drug discounts, no dispensing fees, and lower member copays on prescriptions
- HD increases medication adherence, driving overall healthcare outcomes and savings

Ingredient cost

SAVINGS OPPORTUNITY

\$3,034

% SAVINGS

1.8%

Dispensing fee

SAVINGS OPPORTUNITY

\$628


% SAVINGS

93.8%

Optimizing member health

When members experience the convenience of OptumRx Home Delivery, they have the tools and resources at their fingertips to effectively manage their disease. Ninety-day fills allow members to have their medication when and where they need it, translating to higher medication adherence.

INCREASE IN ADHERENCE



Client results are based on members primarily filling claims in one of these 3 channels.

Improving dispensing accuracy

99.998%

Medication fill accuracy rate at OptumRx Home Delivery compared to ~98.5% at retail.



DID YOU KNOW?

The median wait time for members at retail pharmacies is 45 minutes. With Home Delivery, prescriptions are mailed conveniently to members' homes, eliminating barriers to transportation and travel and removing wait times that come with a retail pharmacy.

UM Opportunity Analysis


UFCW UPE

Opportunities date range: Jan - Dec 2022

Estimated savings: \$24.68 PMPM

UM strategy by program


Utilization Management (UM) evaluates the application of prescribed medication therapy. Using evidence-based medicine, OptumRx UM promotes improvements in affordability, care quality, clinical consistency and patient safety. Based on analysis by OptumRx, its estimated that UFCW UPE can save \$24.68 PMPM by implementing our OptumRx Comprehensive UM program.



Prior Authorization UTILIZERS 318 PMPM SAVINGS \$23.88 PERCENT SAVINGS 12.5%	Quantity Limits UTILIZERS 59 PMPM SAVINGS \$0.80 PERCENT SAVINGS 0.4%
---	--


QL savings is based only on Maximum Daily Dose edits.

Top 5 therapy classes by: Prior Authorization Quantity Limits Step Therapy



Therapy class	Utilizers	Plan paid savings
GLP-1 Receptor Agonists	52	\$279,034
Growth Hormones	1	\$25,380
Agents for Sickle Cell Anemia	1	\$25,143
Endocrine Disorders	2	\$23,606
Inhaled Asthma/COPD Combo	26	\$12,310

Top 5 therapy classes by: Prior Authorization Quantity Limits Step Therapy



Therapy class	Utilizers	Plan paid savings
Impotence Agents	15	\$4,243
Inhaled Asthma/COPD Combo	3	\$4,149
Oral Anticoagulants	4	\$2,761
Inhaled Bronchodilator	15	\$1,437
GLP-1 Receptor Agonists	1	\$954

Vigilant Opportunity Analysis

UFCW UPE

Opportunities date range: Jan - Dec 2022

Estimated annual plan paid savings: \$7.94 PMPM

Your opportunity

- OptumRx has several programs that help to effectively manage costs for higher cost drugs lacking additional value
- Currently, UFCW UPE spends \$5.30 PMPM on Clinical Duplicates for 18 utilizers

TOTAL UTILIZERS

70

6.0% of total

TOTAL RXS

256

1.2% of total

ESTIMATED ANNUAL
PLAN PAID SAVINGS

\$156,732

4.2% of total

Vigilant drug list	Utilizers	Rxs	Estimated annual plan paid savings	Description
Clinical Duplicates	18	65	\$104,717	Excludes new medications with similar composition to existing medications with no significant clinical advantage.
High Cost Brands with Generics	10	40	\$77,608	Excludes certain higher-cost brand products when a clinically equivalent, lower-cost generic option is available.
High Cost Generics	45	124	\$44,558	Excludes specific higher-cost generic products without clinical advantage over other lower-cost generic therapeutic equivalents.
Performance Drivers	2	6	\$33,607	Performance Drivers contains drugs across the Vigilant Drug Program which drive the highest volume of savings for the least amount of member disruption. Excluding these drugs from coverage can capture ~50% of the Vigilant program for ~20% of the disruption to members.
Non-FDA Approved Drugs	11	17	\$1,743	Excludes non-FDA approved products that are considered out of scope for review by the Optum Pharmacy and Therapeutics Committee.
Creams & Patches	3	3	\$823	Excludes topical products for the treatment of pain that are non-FDA approved or considered out of scope for review by the Optum Pharmacy and Therapeutics Committee.
New Drugs to Market	1	1	\$211	Temporarily excludes newly launched products pending OptumRx P&T Committee review.

Total plan paid savings is not necessarily representative of the sum of each vigilant drug list due to overlap across lists.
PA claims are excluded.

Diabetes Opportunity Analysis


UFCW UPE

Opportunities date range: Jan - Dec 2022

Benchmark: LABOR AND TRUST

Total diabetic utilizers: 206

Diabetic utilizers




Compared to benchmark:
10.3%

High risk diabetic
utilizers have higher
annualized plan paid:
\$11,713

**compared to benchmark: \$6,111*


Average annual pharmacy plan paid



Pharmacy utilizers

7.6% of pharmacy utilizers filled a SGLT-2, GLP-1, or DPP-4.


Non-diabetics Low risk diabetics High risk diabetics



Pharmacy plan paid

50.7% of pharmacy plan paid attributed to diabetic members.

Non-diabetics Low risk diabetics High risk diabetics



Meds on Track/Adherence Opportunity Analysis

UFCW UPE

Opportunities date range: Jan - Dec 2022

Total non-adherent utilizers: 101






By engaging members to improve medication adherence through medication consultations and prescriber collaboration, we can help improve members' adherence to their therapies.

- Projected total healthcare savings: \$26,371
- 20.3% of members are non-adherent to their medications

Sort by: Total healthcare savings

Adherence range: 0% – 39% 40% – 59% 60% – 80%



Opioid Utilization

UFCW UPE

Opportunities date range: Sep - Dec 2022

Benchmark: LABOR AND TRUST


Utilizers: 104

4.1% of all Rx claims are filled for an Opioid

Opioid dependence can start in just a few days, and the risk of chronic opioid use increases with each additional day of opioid supplied, starting with the third day. Our Opioid Risk Management program, which includes point of sale, utilization management and retrospective drug utilization edits, are tightly aligned with CDC opioid prescribing guidelines which can help reduce exposure to excessive doses and prevent more members from transitioning from acute to chronic use.

- Opioid prescriptions account for 4.1% of all prescriptions this period, which is 1.6% higher than the benchmark
- 41 high opioid utilizers were identified this period, which is 14.3% higher than the benchmark

Opioid claims



PERCENT NON-COMPLIANT
8.0%

Opioid utilizers



HIGH UTILIZERS


39.4%

41 high utilizers

14.3% over benchmark

High utilizers – [view definition](#)

Claim breakdown



82.5% of all opioid Rx's were filled for short acting opioids. **28** Rx's were for medication assisted therapy (MAT) and **3** were for rescue therapy. CDC guidelines advise prescribers to manage pain with the lowest effective dose and to avoid or carefully justify doses for chronic users >90mg MME/day.

MAT – [view definition](#)

Overdose rescue therapy – [view definition](#)

MME – [view definition](#)

Utilizers by cumulative MED

1 utilizers exceed
180 MED/day

MED Scores	<90	90-179	180-240	>240
Utilizers	95	8	0	1

MED – [view definition](#)

Trend Components

UFCW UPE

Reporting date range: Jan - Dec 2022 vs Jan - Dec 2021

Plan Paid


Total Plan Paid PMPM: \$190.57

Total

Total trend: 18.0%

Benchmark comparison: LABOR AND TRUST


- UFCW UPE's overall trend of 18.0% was 7.0% higher than benchmark
- Specialty spend influenced the trend contributing 63.2% (0.2% higher than benchmark)
- Traditional trend contributed 36.8% (0.2% lower than benchmark)



Traditional

Traditional trend: 9.7%


- Traditional trend contributed 36.8% to the overall trend (18.0%)
- Traditional accounts for 63.7% of overall total plan paid and was down from 68.6% in the prior period



Specialty

Specialty trend: 36.3%

- Specialty trend contributed 63.2% to the overall trend (18.0%)
- Specialty accounts for 36.3% of overall total plan paid and was up from 31.4% in the prior period



Top 20 Drug Names

UFCW UPE

Reporting date range: Jan - Dec 2022 vs Jan - Dec 2021

Benchmark: LABOR AND TRUST

Total Traditional Specialty

Rank												Trend components			
Cu	Pv	Bench	Drug name	Therapy class	Utilzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	% Trend	Top driver	% Top driver
1	3	1	HUMIRA PEN	Chronic Inflammatory Disease	6	40	39.2	\$335,303	\$8,382.58	\$16.98	\$7.10	\$7.66	139.3%	Utilzn	121.0%
2	2	294	SOMAVERT	Growth Hormones	1	4	90.0	\$251,705	\$62,926.19	\$12.75	\$8.55	\$0.05	49.2%	Cost	53.5%
3	1	9	BIKTARVY	HIV-Multiclass Combo	7	43	46.0	\$217,800	\$5,065.11	\$11.03	\$9.60	\$1.70	14.9%	Utilzn	10.1%
4	5	118	ABIRATERONE ACETATE	Oncology	1	14	30.0	\$146,890	\$10,492.17	\$7.44	\$5.04	\$0.17	47.5%	Utilzn	38.1%
5	19	173	MAYZENT	Multiple Sclerosis	1	15	30.0	\$132,856	\$8,857.08	\$6.73	\$1.75	\$0.10	285.5%	Utilzn	255.2%
6	7	8	ELIQUIS	Oral Anticoagulants	37	175	47.9	\$125,599	\$717.71	\$6.36	\$4.33	\$1.90	47.0%	Utilzn	34.6%
7	10	5	JARDIANCE	SGLT-2 Inhibitors & Combos	30	118	58.1	\$107,021	\$906.96	\$5.42	\$3.28	\$2.88	65.0%	Utilzn	59.9%
8	16	309	SOMATULINE DEPOT	Endocrine Disorders	1	11	28.0	\$98,197	\$8,926.98	\$4.97	\$1.87	\$0.05	165.3%	Utilzn	160.5%
9	6	4	TRULICITY	GLP-1 Receptor Agonists	23	74	48.5	\$96,624	\$1,305.73	\$4.89	\$4.48	\$3.15	9.3%	Cost	4.8%
10	28	3	OZEMPIC	GLP-1 Receptor Agonists	23	80	41.4	\$80,337	\$1,004.21	\$4.07	\$1.41	\$3.74	189.1%	Utilzn	190.1%
11	8	27	COSENTYX SENSOREADY PEN	Chronic Inflammatory Disease	1	11	28.0	\$69,199	\$6,290.84	\$3.50	\$3.76	\$0.67	-6.7%	Utilzn	-13.2%
12	9	13	TREMFYA	Chronic Inflammatory Disease	1	5	56.0	\$58,828	\$11,765.59	\$2.98	\$3.37	\$1.46	-11.6%	Utilzn	-8.9%
13	-	25	IBRANCE	Oncology	1	4	28.0	\$55,967	\$13,991.69	\$2.83	\$0.00	\$0.69	-	-	-
14	13	19	XARELTO	Oral Anticoagulants	14	76	48.9	\$50,916	\$669.95	\$2.58	\$2.02	\$1.00	27.5%	Utilzn	33.2%
15	26	28	ENTRESTO	Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	11	52	53.2	\$50,907	\$978.98	\$2.58	\$1.51	\$0.65	70.8%	Utilzn	56.0%
16	14	117	SYM TUZA	HIV-Multiclass Combo	1	12	30.0	\$48,711	\$4,059.24	\$2.47	\$1.98	\$0.17	24.8%	Utilzn	18.4%
17	27	2	STELARA	Chronic Inflammatory Disease	1	4	84.0	\$47,250	\$11,812.45	\$2.39	\$1.43	\$4.19	67.5%	Utilzn	103.0%
18	18	12	FARXIGA	SGLT-2 Inhibitors & Combos	11	40	69.0	\$43,133	\$1,078.32	\$2.18	\$1.87	\$1.47	16.9%	Utilzn	13.5%
19	15	14	LANTUS SOLOSTAR	Insulin	16	56	61.7	\$40,144	\$716.85	\$2.03	\$1.91	\$1.37	6.2%	Cost	8.7%
20	21	134	NUCALA	Asthma	1	12	28.0	\$38,242	\$3,186.80	\$1.94	\$1.67	\$0.14	15.7%	Utilzn	9.3%
Total					144	846	49.2	\$2,095,628	\$2,477.10	\$106.12	\$66.92	\$33.19	58.6%		36.1%
Plan Total					1,167	21,098	48.8	\$3,763,181	\$178.37	\$190.57	\$161.49	\$109.72	18.0%		9.8%

Language Assistance / Non-Discrimination Notice

Asistencia de Idiomas / Aviso de no Discriminación

語言協助 / 不歧視通知

©2023 Optum, Inc. All rights reserved.

PRIVACY

TERMS OF USE

ACCESSIBILITY

Top 20 Drug Names

UFCW UPE

Reporting date range: Jan - Dec 2022 vs Jan - Dec 2021

Benchmark: LABOR AND TRUST

Total Traditional Specialty

Rank													Trend components		
Cu	Pv	Bench	Drug name	Therapy class	Utilzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	% Trend	Top driver	% Top driver
1	1	5	BIKTARVY	HIV-Multiclass Combo	7	43	46.0	\$217,800	\$5,065.11	\$11.03	\$9.60	\$1.70	14.9%	Utilzn	10.1%
2	3	4	ELIQUIS	Oral Anticoagulants	37	175	47.9	\$125,599	\$717.71	\$6.36	\$4.33	\$1.90	47.0%	Utilzn	34.6%
3	4	3	JARDIANCE	SGLT-2 Inhibitors & Combos	30	118	58.1	\$107,021	\$906.96	\$5.42	\$3.28	\$2.88	65.0%	Utilzn	59.9%
4	2	2	TRULICITY	GLP-1 Receptor Agonists	23	74	48.5	\$96,624	\$1,305.73	\$4.89	\$4.48	\$3.15	9.3%	Cost	4.8%
5	14	1	OZEMPIC	GLP-1 Receptor Agonists	23	80	41.4	\$80,337	\$1,004.21	\$4.07	\$1.41	\$3.74	189.1%	Utilzn	190.1%
6	6	9	XARELTO	Oral Anticoagulants	14	76	48.9	\$50,916	\$669.95	\$2.58	\$2.02	\$1.00	27.5%	Utilzn	33.2%
7	13	14	ENTRESTO	Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	11	52	53.2	\$50,907	\$978.98	\$2.58	\$1.51	\$0.65	70.8%	Utilzn	56.0%
8	7	67	SYM TUZA	HIV-Multiclass Combo	1	12	30.0	\$48,711	\$4,059.24	\$2.47	\$1.98	\$0.17	24.8%	Utilzn	18.4%
9	9	7	FARXIGA	SGLT-2 Inhibitors & Combos	11	40	69.0	\$43,133	\$1,078.32	\$2.18	\$1.87	\$1.47	16.9%	Utilzn	13.5%
10	8	8	LANTUS SOLOSTAR	Insulin	16	56	61.7	\$40,144	\$716.85	\$2.03	\$1.91	\$1.37	6.2%	Cost	8.7%
11	36	11	RYBELSUS	GLP-1 Receptor Agonists	8	19	74.2	\$34,545	\$1,818.14	\$1.75	\$0.68	\$0.81	157.9%	Utilzn	142.0%
12	5	6	JANUVIA	DPP-4 Inhibitors & Combos	12	35	59.1	\$31,096	\$888.46	\$1.57	\$2.09	\$1.68	-24.8%	Utilzn	-34.6%
13	12	17	TRELEGY ELLIPTA	Inhaled Asthma/COPD Combo	9	45	34.0	\$28,027	\$622.81	\$1.42	\$1.57	\$0.60	-9.6%	Utilzn	-12.5%
14	39	10	HUMALOG KWIKPEN	Insulin	8	29	46.2	\$27,982	\$964.91	\$1.42	\$0.64	\$0.96	121.3%	Utilzn	86.8%
15	10	36	TOUJEO SOLOSTAR	Insulin	4	17	47.1	\$27,114	\$1,594.93	\$1.37	\$1.62	\$0.28	-15.0%	Utilzn	-31.3%
16	17	138	PRADAXA	Oral Anticoagulants	7	25	73.2	\$26,372	\$1,054.89	\$1.34	\$1.19	\$0.06	12.7%	Utilzn	8.6%
17	15	18	VICTOZA	GLP-1 Receptor Agonists	4	29	38.1	\$25,856	\$891.59	\$1.31	\$1.35	\$0.56	-3.1%	Utilzn	-11.1%
18	18	28	BUPRENORPHINE HYDROCHLORIDE/ NALOXONE HYDROCHLORIDE	Opioid Partial Agonists	7	94	28.2	\$25,202	\$268.11	\$1.28	\$1.07	\$0.31	19.1%	Utilzn	19.0%
19	27	184	BUDESONIDE/ FORMOTEROL FUMARATE DIHYDRATE	Inhaled Asthma/COPD Combo	26	74	38.7	\$25,122	\$339.49	\$1.27	\$0.82	\$0.04	56.0%	Utilzn	59.2%
20	21	94	PREZCOBIX	HIV-Multiclass Combo	2	4	90.0	\$24,748	\$6,186.92	\$1.25	\$0.99	\$0.09	26.6%	Utilzn	18.4%
Total					183	1,097	48.4	\$1,137,255	\$1,036.70	\$57.59	\$44.40	\$23.42	29.7%		25.1%
Plan Total					1,166	20,895	48.9	\$2,398,591	\$114.79	\$121.47	\$110.77	\$58.15	9.7%		5.5%

Language Assistance / Non-Discrimination Notice

Asistencia de Idiomas / Aviso de no Discriminación

語言協助 / 不歧視通知

©2023 Optum, Inc. All rights reserved.

PRIVACY

TERMS OF USE

ACCESSIBILITY

Top 20 Drug Names

UFCW UPE

Reporting date range: Jan - Dec 2022 vs Jan - Dec 2021
Benchmark: LABOR AND TRUST

Total Traditional Specialty

Rank													Trend components		
Cu	Pv	Bench	Drug name	Therapy class	Utilizr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	% Trend	Top driver	% Top driver
1	2	1	HUMIRA PEN	Chronic Inflammatory Disease	6	40	39.2	\$335,303	\$8,382.58	\$16.98	\$7.10	\$7.66	139.3%	Utilzn	121.0%
2	1	150	SOMAVERT	Growth Hormones	1	4	90.0	\$251,705	\$62,926.19	\$12.75	\$8.55	\$0.05	49.2%	Cost	53.5%
3	4	51	ABIRATERONE ACETATE	Oncology	1	14	30.0	\$146,890	\$10,492.17	\$7.44	\$5.04	\$0.17	47.5%	Utilzn	38.1%
4	10	81	MAYZENT	Multiple Sclerosis	1	15	30.0	\$132,856	\$8,857.08	\$6.73	\$1.75	\$0.10	285.5%	Utilzn	255.2%
5	8	156	SOMATULINE DEPOT	Endocrine Disorders	1	11	28.0	\$98,197	\$8,926.98	\$4.97	\$1.87	\$0.05	165.3%	Utilzn	160.5%
6	5	14	COSENTYX SENSOREADY PEN	Chronic Inflammatory Disease	1	11	28.0	\$69,199	\$6,290.84	\$3.50	\$3.76	\$0.67	-6.7%	Utilzn	-13.2%
7	6	6	TREMFYA	Chronic Inflammatory Disease	1	5	56.0	\$58,828	\$11,765.59	\$2.98	\$3.37	\$1.46	-11.6%	Utilzn	-8.9%
8	-	12	IBRANCE	Oncology	1	4	28.0	\$55,967	\$13,991.69	\$2.83	\$0.00	\$0.69	-	-	-
9	14	2	STELARA	Chronic Inflammatory Disease	1	4	84.0	\$47,250	\$11,812.45	\$2.39	\$1.43	\$4.19	67.5%	Utilzn	103.0%
10	12	59	NUCALA	Asthma	1	12	28.0	\$38,242	\$3,186.80	\$1.94	\$1.67	\$0.14	15.7%	Utilzn	9.3%
11	7	3	DUPIXENT	Chronic Inflammatory Disease	2	11	28.0	\$35,133	\$3,193.86	\$1.78	\$2.38	\$2.30	-25.3%	Utilzn	-25.6%
12	-	221	SOFOSBUVIR/ VELPATASVIR	Hepatitis C	1	3	28.0	\$20,442	\$6,813.92	\$1.04	\$0.00	\$0.03	-	-	-
13	-	4	SKYRIZI PEN	Chronic Inflammatory Disease	1	1	28.0	\$18,858	\$18,857.52	\$0.95	\$0.00	\$2.07	-	-	-
14	-	269	OXBRYTA	Agents for Sickle Cell Anemia	1	1	30.0	\$10,750	\$10,750.34	\$0.54	\$0.00	\$0.01	-	-	-
15	29	79	MAVYRET	Hepatitis C	1	1	28.0	\$10,747	\$10,746.97	\$0.54	\$0.00	\$0.10	0.0%	Cost	0.0%
16	17	129	HUMIRA PEN-PS/ UV STARTER	Chronic Inflammatory Disease	1	1	28.0	\$10,683	\$10,682.91	\$0.54	\$0.49	\$0.06	10.6%	Cost	28.9%
17	-	54	XIAFLEX	Enzymes	1	1	28.0	\$5,393	\$5,393.30	\$0.27	\$0.00	\$0.15	-	-	-
18	22	411	GEL-ONE	Osteoarthritis	1	2	34.0	\$4,130	\$2,065.03	\$0.21	\$0.09	\$0.00	136.8%	Cost	118.4%
19	19	331	CYCLOSPORINE MODIFIED	Transplant	1	24	30.0	\$3,251	\$135.46	\$0.16	\$0.15	\$0.01	6.4%	Cost	10.6%
20	18	158	MYCOPHENOLATE MOFETIL	Transplant	2	24	30.0	\$3,114	\$129.73	\$0.16	\$0.16	\$0.05	0.6%	Utilzn	-13.9%
Total					21	189	34.5	\$1,356,937	\$7,179.56	\$68.72	\$37.80	\$19.95	81.8%		33.9%
Plan Total					34	203	34.6	\$1,364,590	\$6,722.12	\$69.10	\$50.72	\$51.57	36.3%		15.9%

Selected Pipeline Drugs

UFCW UPE

Reporting date range: Jan - Dec 2022

Drug review

Projected annual ingredient cost PMPM: \$0.05

RSV Vaccines (GSK-3844766A and PF-06928316)

Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. However, some patients may develop severe RSV infection which may result in a hospitalization. Each year, it is estimated that between 60,000 to 120,000 older adults in the U.S. are hospitalized and 6,000 to 10,000 of them die due to infection. In the adult population, there are no FDA approved treatments or vaccines for RSV.

Both Pfizer and GSK have RSV vaccines currently under review by the FDA for prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged ≥ 60 years. In the pivotal trials, both vaccines (administered as a single-dose) significantly reduced the incidence of RSV-LRTD. The need for revaccination, and the time interval, is not yet known.

PRIMARY INDICATION
RSV infection

MANUFACTURER
Pfizer, GSK

ROUTE OF ADMINISTRATION
IM

CURRENTLY APPROVED TREATMENT (OTHER)
None


EXPECTED APPROVAL DATE
5/2023

PRELIMINARY ORX STRATEGY
None

PROJECTED UTILIZERS

YEAR 1	YEAR 2	YEAR 3
15	31	46

INGREDIENT COST PMPM



Anticipated utilization and PMPM costs are based upon Book of Business disease prevalence



According to our estimates, cancer will account for the largest therapeutic area in the pipeline, followed by neurology and infectious diseases. Rare diseases will continue to be a central focus of drug development; Approximately 40 - 50% of pipeline drugs that could reach the market in 2022 will have orphan designations for small targeted populations.

Selected Pipeline Drugs

UFCW UPE

Reporting date range: Jan - Dec 2022

Traditional

Projected annual ingredient cost PMPM: \$0.88

Drug name	Indication	Route of admin	Approval date	Projected utilizers	Projected annual PMPM ing cost
Tirzepatide	Chronic weight management	SC	Late 2023	1	\$0.55
Fezolinetant	Vasomotor symptoms associated with menopause	Oral	2/22/2023	2	\$0.16
Obeticholic acid	Nonalcoholic steatohepatitis	Oral	6/23/2023	0	\$0.12
RSV Vaccines	RSV infection	IM	5/2023	15	\$0.05
Omecamtiv mecarbil	Chronic heart failure	Oral	2/28/2023	0	\$0.00

Anticipated utilization and PMPM costs are based upon Book of Business disease prevalence

Selected Pipeline Drugs

UFCW UPE

Reporting date range: Jan - Dec 2022

Specialty

Projected annual ingredient cost PMPM: \$0.50

Drug name	Indication	Route of admin	Approval date	Projected utilizers	Projected annual PMPM ing cost
Roctavian (valoctocogene roxaparvovec)	Hemophilia A	IV	1H2023	0	\$0.65
Delandistrogene moxeparvovec	Duchenne muscular dystrophy	IV	5/29/2023	0	\$0.45
Tzield (teplizumab)	Delay of type 1 diabetes mellitus	IV	11/17/2022	0	\$0.17
Exagamglogene autotemcel	β-thalassemia	IV	4Q2023	0	\$0.12
Exagamglogene autotemcel	Sickle cell disease	IV	4Q2023	0	\$0.08
Relyvrio (sodium phenylbutyrate/taurursodiol)	Amyotrophic lateral sclerosis	Oral	9/29/2022	0	\$0.07
Sparsentan	IgA nephropathy	Oral	2/17/2023	0	\$0.07
Hemgenix (etranacogene dezaparvovec)	Hemophilia B	IV	11/22/2022	0	\$0.05
Sotyktu (deucravacitinib)	Plaque psoriasis	Oral	9/9/2022	0	\$0.02
Palopecteriparatide	Hypoparathyroidism	SC	4/30/2023	0	\$0.02
Pegcetacoplan	Geographic atrophy	Intravitreal	2/26/2023	0	\$0.01
Onpattro (patisiran)	Transthyretin amyloidosis with cardiomyopathy	IV	10/8/2023	0	\$0.01
Daprodustat	Chronic kidney disease - anemia	Oral	2/1/2023	0	\$0.00
Beta-amyloid targeted antibodies (lecanemab, donanemab)	Alzheimer's disease	IV	1Q2023	0	\$0.00
Actemra (tocilizumab) biosimilars	Indications expected to mirror branded Actemra	IV/SC	2023 - 2024	0	-\$0.03
Simponi (golimumab) biosimilars	Indications expected to mirror branded Simponi	IV/SC	2/2024	0	-\$0.06
Stelara (ustekinumab) biosimilars	Indications expected to mirror branded Stelara	IV/SC	2H2023 - Early 2024	0	-\$0.36
Humira (adalimumab) biosimilars	Indications expected to mirror branded Humira	SC	1/2023	1	-\$0.77

Anticipated utilization and PMPM costs are based upon Book of Business disease prevalence

Selected Pipeline Drugs

UFCW UPE

Reporting date range: Jan - Dec 2022

Generics

Projected ingredient cost PMPM savings: \$8.26

						Proj. annual ing cost savings	
Brand drug name	Generic drug name	Disease state	Expected launch date	Utilizers	Actual brand drug ing cost	Year 1	Year 2
Trokendi XR	topiramate	Seizure Disorders	01/30/2023	1	\$2,562	\$1,509	\$2,145
Latuda	lurasidone	Antipsychotics	02/21/2023	0	\$0	\$0	\$0
Aubagio	teriflunomide	Multiple Sclerosis	03/12/2023	0	\$0	\$0	\$0
Forteo	teriparatide	Osteoporosis	04/01/2023	0	\$0	\$0	\$0
Kombiglyze XR	saxagliptin/metformin	Diabetes	04/01/2023	1	\$5,324	\$3,691	\$4,503
Onglyza	saxagliptin	Diabetes	04/01/2023	1	\$153	\$107	\$131
Livalo	pitavastatin	Cholesterol Lowering Agents	05/02/2023	2	\$5,421	\$3,779	\$4,609
Dulera	formoterol fumarate/ mometasone furoate	Asthma / COPD	07/01/2023	4	\$5,168	\$3,647	\$4,449
Spiriva Handihaler	tiotropium	Asthma / COPD	07/01/2023	8	\$22,132	\$13,130	\$18,811
Vyvanse	lisdexamfetamine	ADHD & Narcolepsy	08/24/2023	6	\$15,210	\$10,758	\$13,124
VOTRIENT	pazopanib	Oncology	10/19/2023	0	\$0	\$0	\$0
Myrbetriq	mirabegron	Overactive Bladder / Incontinence	01/01/2024	6	\$18,914	\$13,775	\$16,803
TASIGNA	nilotinib	Oncology	01/05/2024	0	\$0	\$0	\$0
ISENTRESS	raltegravir	HIV	04/04/2024	0	\$0	\$0	\$0
SAXENDA	liraglutide	Weight Loss	05/12/2024	0	\$0	\$0	\$0
VICTOZA	liraglutide	Diabetes	06/22/2024	4	\$28,852	\$21,660	\$26,422
Sprycel	dasatinib	Oncology	09/01/2024	0	\$0	\$0	\$0